Santen Pharmaceutical Co., Ltd
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-126 that is in Phase 2b clinical trial; DE-128, which is in Phase 2/3 clinical trial; DE-130A that is in Phase III clinical trial; and DE-117. In addition, the company provides DE-114A to treat allergic conjunctivitis that has completed phase 3 clinical trial; DE-076C for the treatment of Vernal keratoconjunctivitis; DE-109, which is in Phase 3 clinical trial to treat uveitis; and DE-122 that is in Phase 2a clinical trial for the treatment of wet age-related macular degeneration. Further, it intends to initiate Phase 2/3 clinical trial for DE-127 to treat myopia; and MD-16 for the treatment of cataract that has completed Phase III clinical trial. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Show More...
-
Website http://www.santen.com
-
Sector Healthcare
-
Industry Drug Manufacturers-General
-
Last Quote 9.50 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-03 2011-03 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 TTM Earnings Per Share JPY 43.97 49.88 39.35 39.1 47.63 57.93 128.41 52.76 86.42 78.43 71.88 Dividends JPY 18.0 20.0 20.0 20.0 22.0 25.0 26.0 26.0 26.0 26.0 Payout Ratio % * 36.0 40.6 51.7 46.4 46.3 17.6 46.2 31.9 33.9 36.2 Shares Mil 426.0 428.0 436.0 422.0 414.0 415.0 416.0 412.0 408.0 407.0 401.0 Book Value Per Share * EUR 3.06 3.39 3.16 3.05 3.64 4.9 5.22 5.22 5.99 6.35 Free Cash Flow Per Share * EUR 0.35 0.43 0.3 0.34 0.43 0.42 -0.11 0.56 0.52 Return on Assets % 11.78 12.13 8.95 8.29 7.94 8.98 16.18 6.8 9.92 8.19 7.25 Financial Leverage (Average) 1.21 1.18 1.21 1.21 1.28 1.44 1.37 1.28 1.36 1.34 1.35 Return on Equity % 14.24 14.51 10.68 10.01 9.88 12.23 22.63 8.99 13.09 11.08 9.63 Return on Invested Capital % 14.17 14.46 10.65 9.98 9.85 12.06 22.83 9.17 12.9 11.59 9.8 Interest Coverage 551.19 864.17 129.54 54.26 21.33 91.46 15.96 25.51 Current Ratio 4.7 5.71 5.12 4.91 3.99 2.67 2.66 2.94 2.94 3.21 3.52 Quick Ratio 3.99 4.89 4.26 3.91 3.29 2.27 2.27 2.33 2.39 2.57 2.89 Debt/Equity